Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.

Saved in:
Bibliographic Details
Title: Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.
Authors: Al-Jarshawi M; Centre for Health Informatics, Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. mustafa.al-jarshawi@manchester.ac.uk.; Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, UK. mustafa.al-jarshawi@manchester.ac.uk.; Honorary Clinical Lecturer, Institute of Health Sciences Education, Queen Mary University of London, London, UK. mustafa.al-jarshawi@manchester.ac.uk.; Council Member, European Society of Cardiology (ESC) Council of Cardio-Oncology, Sophia Antipolis, France. mustafa.al-jarshawi@manchester.ac.uk.; NIHR Academy member, National Institute for Health & Care Research, Leeds, UK. mustafa.al-jarshawi@manchester.ac.uk., Cole A; Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, UK., Bagur R; Department of Cardiology, London Health Sciences Centre, Western University, London, ON, Canada., Wang HY; Coronary Heart Disease Center and Cardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Ng CH; Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore., Yu D; School of Medicine, Keele University, Keele, UK., Chew NWS; Department of Cardiology, National University Heart Centre, National University Health System, Singapore, Singapore., Mamas MA; Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, UK.
Source: Cardiovascular diabetology. Endocrinology reports [Cardiovasc Diabetol Endocrinol Rep] 2026 May 22; Vol. 12 (1). Date of Electronic Publication: 2026 May 22.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 9918994893106676 Publication Model: Electronic Cited Medium: Internet ISSN: 3059-4057 (Electronic) Linking ISSN: 30594057 NLM ISO Abbreviation: Cardiovasc Diabetol Endocrinol Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:3059-4057
DOI:10.1186/s40842-026-00299-z